PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29599345
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the
      Upper and Lower Urinary Tract.
PG  - 2241-2245
AB  - BACKGROUND/AIM: To evaluate the clinicopathological characteristics and prognosis
      of squamous cell carcinoma (SCC) of the urinary tract (UT) urothelium, and
      investigate the utility of perioperative chemotherapy. PATIENTS AND METHODS:
      Thirty-three patients diagnosed with SCC in renal pelvis, ureter and bladder at
      the Kanazawa University between 2007 and 2017 were included in this retrospective
      study. Cancer-specific survival (CSS) rates according to cancer stage and
      neoadjuvant chemotherapy (NAC) were determined. RESULTS: Among the entire cohort,
      two-year CSS rates were 100%, 75%, 47% and 0% in stages I, II, III and IV,
      respectively, with a significant correlation between CSS and cancer stage
      (p=0.0063). Sixteen patients underwent radical surgery, and seven patients
      received NAC; however, there were no significant differences in CSS rates among
      patients stratified by NAC (p=0.7043). CONCLUSION: Worse cancer stage for SCC of 
      UT urothelium was associated with worse prognosis. Given the poor efficacy of NAC
      in these patients, surgical treatment should be preferred.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Makino, Tomoyuki
AU  - Makino T
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Izumi, Kouji
AU  - Izumi K
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan [email protected]
FAU - Natsagdorj, Ariunbold
AU  - Natsagdorj A
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Iwamoto, Hiroaki
AU  - Iwamoto H
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kadomoto, Suguru
AU  - Kadomoto S
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Naito, Renato
AU  - Naito R
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Kadono, Yoshifumi
AU  - Kadono Y
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
FAU - Mizokami, Atsushi
AU  - Mizokami A
AD  - Department of Integrative Cancer Therapy and Urology, Kanazawa University
      Graduate School of Medical Science, Kanazawa, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - *Carcinoma, Squamous Cell/diagnosis/drug therapy/mortality/surgery
MH  - Chemotherapy, Adjuvant
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - *Kidney Neoplasms/diagnosis/drug therapy/mortality/surgery
MH  - Kidney Pelvis/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Nephrectomy
MH  - Perioperative Period
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - *Ureteral Neoplasms/diagnosis/drug therapy/mortality/surgery
MH  - Urinary Bladder Neoplasms/diagnosis/drug therapy/mortality/*surgery
OTO - NOTNLM
OT  - *Squamous cell carcinoma
OT  - *bladder
OT  - *renal pelvis
OT  - *squamous differentiation
OT  - *ureter
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/01/30 00:00 [received]
PHST- 2018/02/18 00:00 [revised]
PHST- 2018/02/20 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2241 [pii]
AID - 10.21873/anticanres.12467 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2241-2245. doi: 10.21873/anticanres.12467.